Concierte una cita por teléfono
Concierte una cita con MyChart
Reserva con MyChart
Llame para obtener ayuda con el proceso de referencia
At Boston Medical Center, the Center for Addiction Treatment for AdoLescent/Young adults who use SubsTances (CATALYST) program helps teens and young adults who use alcohol or drugs. Our team provides access to a wide range of services including primary care, harm reduction, assessment and treatment of substance use disorders, psychiatry, psychotherapy, and recovery support for patients through age 25 and their families.
For patients 21 and under
Yawkey Center 617.414.6655
For patients 22-25
Shapiro Center 617.414.6655
Conditions We Treat
Tratamientos y Servicios
- Assessment, diagnosis, and treatment of substance use disorders (SUDs)
- Assessment, diagnosis and treatment of psychiatric disorders
- Primary care including HIV screening, Pre-exposure Prophylaxis, Hepatitis C screening and treatment, screening for other sexually transmitted infections, and family planning
- Overdose education and naloxone kits
- Parent guidance for families
- Additional support with navigation and recovery coaching
Patients can either receive primary care Boston Medical Center OR get a referral from their existing primary care provider. The CATALYST Clinic team can help patients schedule and establish primary care at BMC in addition to their substance use care/services if desired.
We are a multidisciplinary team consisting of physicians board certified addiction medicine and psychiatry, licensed clinical social workers, a nurse care manager with addiction certification, a patient navigator, recovery coaches, and a program manager. We offer evidence-based treatment and are adept at working with young patients who use substances. Our team based-care allows us to provide the best care for patients and their families creating a clear path to healthy lives.
Juliana Scherer, LCSW, MPH
Lydia Reyes, CARC
Recursos del Paciente
Resumen de la Investigación
Receipt of Addiction Treatment After Opioid Overdose Among Medicaid-Enrolled Adolescents and Young Adults - Alinsky RH, Zima BT, Rodean J, et al. s. JAMA Pediatr. 2020;174(3):e195183. doi:10.1001/jamapediatrics.2019.5183
Opioid Prescribing Patterns and Subsequent Overdose - Hadland SE, Bagley SM. . JAMA Pediatr. 2020;174(2):124-125. doi:10.1001/jamapediatrics.2019.4885
Alcohol Use Disorders in Adolescents - Bagley SM, Levy S, Schoenberger SF. . Pediatr Clin North Am. 2019;66(6):1063-1074. doi:10.1016/j.pcl.2019.08.003
Incidence and Characteristics of Nonfatal Opioid Overdose Among Youths Aged 11 to 24 Years by Sex - Bagley SM, Gai MJ, Earlywine JJ, Schoenberger SF, Hadland SE, Barocas JA.. JAMA Netw Open. 2020;3(12):e2030201. Published 2020 Dec 1. doi:10.1001/jamanetworkopen.2020.30201
Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose - Bagley SM, Larochelle MR, Xuan Z, et al.. Ann Emerg Med. 2020;75(1):29-38. doi:10.1016/j.annemergmed.2019.07.030
Non-fatal opioid-related overdoses among adolescents in Massachusetts 2012-2014. - Chatterjee A, Larochelle MR, Xuan Z, et al. Drug Alcohol Depend. 2019;194:28-31. doi:10.1016/j.drugalcdep.2018.09.020
Evidence-Based Treatment of Young Adults With Substance Use Disorders - Hadland SE, Yule AM, Levy SJ, Hallett E, Silverstein M, Bagley SM. . Pediatrics. 2021;147(Suppl 2):S204-S214. doi:10.1542/peds.2020-023523D
A commentary on the impact of COVID-19 on engagement of youth with substance use and co-occurring psychiatric disorders. - Bagley SM, Hadland SE, Yule AM. J Subst Abuse Treat. 2021;121:108175. doi:10.1016/j.jsat.2020.108175
Age-based preferences for risk communication in the fentanyl era: 'A lot of people keep seeing other people die and that's not enough for them'. - Gunn CM, Maschke A, Harris M, et al. Addiction. 2021;116(6):1495-1504. doi:10.1111/add.15305
Opioid use disorder and overdose among youth following an initial opioid prescription. - Hadland SE, Bagley SM, Gai MJ, et al. Addiction. 2021;116(10):2790-2800. doi:10.1111/add.15487
Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings : Harm Reduction in Outpatient Addiction Treatment - Taylor JL, Johnson S, Cruz R, Gray JR, Schiff D, Bagley SM. [published online ahead of print, 2021 Jun 22]. J Gen Intern Med. 2021;1-10. doi:10.1007/s11606-021-06904-4
Engaging the Family in the Care of Young Adults With Substance Use Disorders. - Bagley SM, Ventura AS, Lasser KE, Muench F. Pediatrics. 2021;147(Suppl 2):S215-S219. doi:10.1542/peds.2020-023523C
Información Sobre Residencia y Becas
Addiction Medicine Fellowship
The mission of the Grayken Fellowship in Addiction Medicine is to train physician addiction medicine leaders in clinical care, research, education, public health, and advocacy to improve addiction care for people vulnerable to health inequities due to race, ethnicity, gender, poverty, age, disability or stigmatizing illness.
The Grayken Addiction Medicine Fellowship Program is a 1 or 2 year fellowship. There is also a 3-year combined Infectious Disease-Addiction Medicine Fellowship and a 2-year Fellowship in Maternal Health Addiction. Fellows are mentored by our multidisciplinary faculty from Internal Medicine, Infectious Disease, Emergency Medicine, Obstetrics & Gynecology and Addiction Psychiatry. The Grayken Fellowship in Addiction Medicine is accredited by the ACGME. Click here to learn more
Latest from HealthCity
Recovery coach Tyshaun Perryman shared a candid story of his own father's experience of civil commitment for substance use treatment.
Despite advice from medical groups, nearly two-thirds of patients studied didn't receive medication for opioid use disorder.
BMC experts testified in support of eliminating the requirement to report abuse and neglect for babies born with neonatal opioid withdrawal syndrome.
Clinicians who treat this population are in a unique position to advocate for partnerships between community entities and health centers.
Experts underline that early intervention and tailored services are necessary to prevent lifelong harm for this vulnerable age group.
New provider principles lay out how to treat patients according to their age-specific needs — and elevate national discussions on systemic changes.
Better health outcomes hinge on positive social support for young adults with SUD, but uninformed family members can unintentionally cause harm.
As the pandemic surges, the urgency of adjusting to find the most useful approach to SUD treatment in a critical population is growing.
Youth opioid overdose deaths increasingly involve cocaine and other substances rather than opioids alone, research finds.
Amid widespread prescription stimulant misuse, new research begins to characterize how pharmaceutical marketing may play a role.
Research highlights opportunity to intervene with adolescents, a group particularly vulnerable to addiction and overdose.
Only 1 in 4 diagnosed youths receives timely treatment with medication for opioid use disorder.